News

Three big drugs start funding run

Posted 4 June 2026 AM

GSK’s hepatitis B drug bepirovirsen, Novartis’ Pluvicto, and Eisai’s Alzheimer’s disease drug Leqembi, are all named in applications to be considered by an MSAC subcommittee, potentially paving the path for these medicines to be funded via the MBS or the PBS in the future.

All three applications will be considered by the PICO Advisory Sub Committee (PASC) in August before being considered by the Evaluation Sub Committee and finally MSAC.

To see the whole article, please login